Volume 17, Number 9—September 2011
Research
Seroepidemiologic Study of Pandemic (H1N1) 2009 during Outbreak in Boarding School, England
Sandra Johnson, Chikwe Ihekweazu
, Pia Hardelid, Nika Raphaely, Katja Hoschler, Alison Bermingham, Muhammad Abid, Richard G. Pebody, Graham Bickler, John T. Watson, and Éamonn O’Moore
, Pia Hardelid, Nika Raphaely, Katja Hoschler, Alison Bermingham, Muhammad Abid, Richard G. Pebody, Graham Bickler, John T. Watson, and Éamonn O’Moore
Table 3
Multivariable analysis of all study participants in relation to having ARI or serology-confirmed infection during outbreak of pandemic (H1N1) 2009, England*
| Variable | AOR (95% CI) for ARI in questionnaire sample | AOR (95% CI) for positive test result in matched sample |
|---|---|---|
| Age group, y | ||
| 13–15 | 1 | 1 |
| 16–18 | 1.57 (0.98–2.53) | 1.85 (0.95–3.60) |
| 20–49 | 1.00 (0.53–1.89) | 0.30 (0.12–0.73) |
| >50 |
0.66 (0.32–1.34) |
0.20 (0.08–0.53) |
| Took antiviral drugs for PEP† | ||
| No | 1 | |
| Yes |
0.41 (0.27–0.61) |
0.55 (0.30–0.99) |
| Seasonal Influenza vaccine | ||
| No | 1 | 1 |
| Yes | 1.01 (0.63–1.62) | 1.81 (0.91–3.59) |
*For ARI, n = 654 who completed questionnaires; for serology-confirmed infection, n = 333 who completed questionnaires and had a matched serology sample. ARI, acute respiratory infection; AOR, adjusted odds ratio; CI, confidence interval; PEP, postexposure prophylaxis.
†Persons who reported taking treatment dose of antiviral agents were excluded.
Page created: September 06, 2011
Page updated: September 06, 2011
Page reviewed: September 06, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.